- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
BALAXI PHARMACEUTICALS LIMITED — Board Meeting, 28-05-2026: Outcome of Board Meeting
28-05-2026 | 07:23 pm
28-05-2026 | 07:23 pm
Balaxi Pharma secured its Jadcherla plant's manufacturing license, gearing up to commercialize Paracetamol & Piroxicam. The board approved FY26 consolidated revenue of ₹270.17 Cr and net profit of ₹1.42 Cr. Ms. Akshita Ostwal's re-appointment as Independent Director was also proposed.
No comments yet. Be the first to comment!